Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Explaining the preponderance of Kras mutations in human cancer: An isoform-specific function in stem cell expansion.

Quinlan MP, Settleman J.

Cell Cycle. 2008 May 15;7(10):1332-5. Epub 2008 Mar 11.

PMID:
18418066
2.

Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion.

Quinlan MP, Quatela SE, Philips MR, Settleman J.

Mol Cell Biol. 2008 Apr;28(8):2659-74. doi: 10.1128/MCB.01661-07. Epub 2008 Feb 11.

3.

A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.

Bentley C, Jurinka SS, Kljavin NM, Vartanian S, Ramani SR, Gonzalez LC, Yu K, Modrusan Z, Du P, Bourgon R, Neve RM, Stokoe D.

Biochem J. 2013 Jun 1;452(2):313-20. doi: 10.1042/BJ20121578.

PMID:
23496764
4.

The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.

Ouerhani S, Elgaaied AB.

Cancer Biomark. 2011-2012;10(6):259-66. doi: 10.3233/CBM-2012-0254.

PMID:
22820081
5.

Oncogenic KRAS induces progenitor cell expansion and malignant transformation in zebrafish exocrine pancreas.

Park SW, Davison JM, Rhee J, Hruban RH, Maitra A, Leach SD.

Gastroenterology. 2008 Jun;134(7):2080-90. doi: 10.1053/j.gastro.2008.02.084. Epub 2008 Mar 5.

6.

Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.

Sasaki H, Okuda K, Kawano O, Endo K, Yukiue H, Yokoyama T, Yano M, Fujii Y.

Oncol Rep. 2007 Sep;18(3):623-8.

PMID:
17671710
7.

Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.

To MD, Rosario RD, Westcott PM, Banta KL, Balmain A.

Oncogene. 2013 Aug 22;32(34):4028-33. doi: 10.1038/onc.2012.404. Epub 2012 Sep 3.

8.

PIK3CA, HRAS and KRAS gene mutations in human penile cancer.

Andersson P, Kolaric A, Windahl T, Kirrander P, Söderkvist P, Karlsson MG.

J Urol. 2008 May;179(5):2030-4. doi: 10.1016/j.juro.2007.12.040. Epub 2008 Mar 19.

PMID:
18355852
9.

The role of wild type RAS isoforms in cancer.

Zhou B, Der CJ, Cox AD.

Semin Cell Dev Biol. 2016 Oct;58:60-9. doi: 10.1016/j.semcdb.2016.07.012. Epub 2016 Jul 13. Review.

10.

Oncogenic activating mutations are associated with local copy gain.

Modrek B, Ge L, Pandita A, Lin E, Mohan S, Yue P, Guerrero S, Lin WM, Pham T, Modrusan Z, Seshagiri S, Stern HM, Waring P, Garraway LA, Chant J, Stokoe D, Cavet G.

Mol Cancer Res. 2009 Aug;7(8):1244-52. doi: 10.1158/1541-7786.MCR-08-0532. Epub 2009 Aug 11.

11.

[A Kras-specific function in cancer initiation].

Quinlan MP, Settleman J.

Ai Zheng. 2008 Jul;27(7):673-4. Chinese. No abstract available.

PMID:
18606056
12.

Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.

Janzarik WG, Kratz CP, Loges NT, Olbrich H, Klein C, Schäfer T, Scheurlen W, Roggendorf W, Weiller C, Niemeyer C, Korinthenberg R, Pfister S, Omran H.

Neuropediatrics. 2007 Apr;38(2):61-3.

PMID:
17712732
13.

Concurrent oncogene mutation profile in Chinese patients with stage Ib lung adenocarcinoma.

Wen YS, Cai L, Zhang XW, Zhu JF, Zhang ZC, Shao JY, Zhang LJ.

Medicine (Baltimore). 2014 Dec;93(29):e296. doi: 10.1097/MD.0000000000000296.

14.

Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.

Georgieva IA, Mauerer A, Groesser L, Herschberger E, Aslanidis C, Dietmaier W, Landthaler M, Hafner C.

Am J Dermatopathol. 2014 Aug;36(8):635-42. doi: 10.1097/DAD.0b013e31828c0542.

PMID:
23739246
15.

Climbing RAS, the everest of oncogenes.

Russo M, Di Nicolantonio F, Bardelli A.

Cancer Discov. 2014 Jan;4(1):19-21. doi: 10.1158/2159-8290.CD-13-0906.

16.

Rare codons regulate KRas oncogenesis.

Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM.

Curr Biol. 2013 Jan 7;23(1):70-5. doi: 10.1016/j.cub.2012.11.031. Epub 2012 Dec 13.

17.

Cre/loxP-regulated transgenic zebrafish model for neural progenitor-specific oncogenic Kras expression.

Seok SH, Na YR, Han JH, Kim TH, Jung H, Lee BH, Emelyanov A, Parinov S, Park JH.

Cancer Sci. 2010 Jan;101(1):149-54. doi: 10.1111/j.1349-7006.2009.01393.x. Epub 2009 Oct 10.

18.

High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Kiessling MK, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, Macconaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R.

Blood. 2011 Feb 24;117(8):2433-40. doi: 10.1182/blood-2010-09-305128. Epub 2011 Jan 5.

19.

Kras regulatory elements and exon 4A determine mutation specificity in lung cancer.

To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A.

Nat Genet. 2008 Oct;40(10):1240-4. doi: 10.1038/ng.211. Epub 2008 Aug 31.

20.

Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.

Schulten HJ, Salama S, Al-Ahmadi A, Al-Mansouri Z, Mirza Z, Al-Ghamdi K, Al-Hamour OA, Huwait E, Gari M, Al-Qahtani MH, Al-Maghrabi J.

Anticancer Res. 2013 Nov;33(11):4779-84.

PMID:
24222113

Supplemental Content

Support Center